Richard E Gilbert

List of Publications by Citations

44 papers	2,528 citations	22 h-index	44 g-index
44 ext. papers	3,048 ext. citations	6.5 avg, IF	5.05 L-index

#	Paper	IF	Citations
44	Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. *Canadian Journal of Cardiology*, **2018**, 34, 506-525	3.8	348
43	Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. *Canadian Journal of Cardiology*, **2016**, 32, 569-88	3.8	314
42	The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Canadian Journal of Cardiology*, **2015**, 31, 549-68	3.8	222
41	Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. *Canadian Journal of Cardiology*, **2017**, 33, 557-576	3.8	205
40	The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. *Canadian Journal of Cardiology*, **2014**, 30, 485-501	3.8	198
39	Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. *Lancet, The*, **2015**, 385, 2107-17	40	188
38	Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children. *Canadian Journal of Cardiology*, **2020**, 36, 596-624	3.8	139
37	Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. *Circulation: Heart Failure*, **2009**, 2, 129-37	7.6	92
36	Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. *Kidney International*, **2014**, 86, 693-700	9.9	81
35	Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 298, H1415-25	5.2	81
34	Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. *Journal of Molecular and Cellular Cardiology*, **2005**, 39, 213-21	5.8	63
33	Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction. *JACC Basic To Translational Science*, **2019**, 4, 27-37	8.7	49
32	DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. *Cardiovascular Therapeutics*, **2013**, 31, 259-67	3.3	49
31	Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. *Diabetes Care*, **2007**, 30, 995-6	14.6	42
30	Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1996-2000	6.7	37
29	Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease. *PLoS ONE*, **2016**, 11, e0144640	3.7	37
28	A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. *PLoS ONE*, **2012**, 7, e47160	3.7	35

27	The cardiac (pro)renin receptor is primarily expressed in myocyte transverse tubules and is increased in experimental diabetic cardiomyopathy. *Journal of Hypertension*, **2011**, 29, 1175-84	1.9	34
26	Sirtuin 1 Activation Reduces Transforming Growth Factor-β1-Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. *American Journal of Pathology*, **2017**, 187, 80-90	5.8	30
25	Early-outgrowth bone marrow cells attenuate renal injury and dysfunction via an antioxidant effect in a mouse model of type 2 diabetes. *Diabetes*, **2012**, 61, 2114-25	0.9	29
24	SGLT2 inhibitors: β-blockers for the kidney?. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 814	18.1	28
23	Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. *Cardiovascular Diabetology*, **2020**, 19, 13	8.7	23
22	Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. *Cardiovascular Diabetology*, **2018**, 17, 99	8.7	21
21	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). *Circulation*, **2018**, 137, 88-90	16.7	19
20	Recombinant N-Terminal Slit2 Inhibits TGF-β-Induced Fibroblast Activation and Renal Fibrosis. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 2609-15	12.7	19
19	Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. *JACC: Cardiovascular Imaging*, **2021**, 14, 1164-1173	8.4	18
18	Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials. *Diabetes Therapy*, **2017**, 8, 451-458	3.6	17
17	Overexpression of the Severe Acute Respiratory Syndrome Coronavirus-2 Receptor, Angiotensin-Converting Enzyme 2, in Diabetic Kidney Disease: Implications for Kidney Injury in Novel Coronavirus Disease 2019. *Canadian Journal of Diabetes*, **2021**, 45, 162-166.e1	2.1	13
16	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. *Nephrology Dialysis Transplantation*, **2020**, 35, 895-897	4.3	12
15	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. *Canadian Journal of Diabetes*, **2016**, 40, 247-57	2.1	12
14	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. *American Journal of Medicine*, **2017**, 130, 1465.e27-1465.e39	2.4	10
13	Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury. *American Journal of Physiology - Heart and Circulatory Physiology*, **2014**, 307, H337-45	5.2	10
12	SIRT1 activation attenuates β-cell hyperplasia, hyperglucagonaemia and hyperglycaemia in STZ-diabetic mice. *Scientific Reports*, **2018**, 8, 13972	4.9	10
11	Conditioned Medium from Early-Outgrowth Bone Marrow Cells Is Retinal Protective in Experimental Model of Diabetes. *PLoS ONE*, **2016**, 11, e0147978	3.7	9
10	Reversing CXCL10 Deficiency Ameliorates Kidney Disease in Diabetic Mice. *American Journal of Pathology*, **2018**, 188, 2763-2773	5.8	8

9	Augmenting endothelial repair in diabetes: role of bone marrow-derived cells. *Canadian Journal of Diabetes*, **2013**, 37, 315-8	2.1	6
8	Renal histology in diabetic nephropathy predicts progression to end-stage kidney disease but not the rate of renal function decline. *BMC Nephrology*, **2020**, 21, 285	2.7	6
7	The perils of clinical trials. *Kidney International*, **2014**, 85, 745-7	9.9	5
6	Impaired SIRT1 activity leads to diminution in glomerular endowment without accelerating age-associated GFR decline. *Physiological Reports*, **2019**, 7, e14044	2.6	3
5	Reduction in the incidence of myocardial infarction with sodium-glucose linked cotransporter-2 inhibitors: evident and plausible. *Cardiovascular Diabetology*, **2019**, 18, 6	8.7	3
4	Diabetic kidney disease 2.0: the treatment paradigm shifts. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 820-821	18.1	2
3	Heart failure in SAVOR-TIMI 53: The hindsight of diabetic retinopathy. *Journal of Diabetes*, **2015**, 7, 304-6	3.8	1
2	The Goto Kakizaki rat: Impact of age upon changes in cardiac and renal structure, function. *PLoS ONE*, **2021**, 16, e0252711	3.7	0
1	Henry Krum, Pioneering Heart Failure Researcher. *European Journal of Heart Failure*, **2016**, 18, 125-6	12.3	